SCROLL

For Life: Stories

01

Supporting Healthcare Professionals and Human Health. “Otsuka the IV Solution Leader” Was Not Built in a Day.

02

Released Oct. 1st

03

Released Nov. 1st

04

Released Dec.

  • 01
  • 02
  • 03
  • 04
  • 05
  • 06
  • 07
  • 08
  • 09
  • 10

for Life

100th year Symbol and Tagline

Chronology

Otsuka Holdings Co., Ltd. Established

Otsuka Holdings Co., Ltd. oversees Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Otsuka Warehouse Co., Ltd., and Otsuka Chemical Co., Ltd. as direct subsidiaries.
Photograph: Akihito Otsuka appointed Chairman and Representative Director

Otsuka Holdings publically listed

Otsuka Holdings was listed on the First Section of the Tokyo Stock Exchange.
Photograph: Chairman and Representative Director Akihiko Otsuka rings the bell at the listing ceremony

90th anniversary of founding of Otsuka group

A ceremony to celebrate the 90th anniversary of the founding of the Otsuka group was held at Otsuka Museum of Art on September 5, 2011.

Otsuka Holdings joins UN Global Compact

Otsuka Holdings became a signatory to the United Nations Global Compact and committed to adhere to its 10 principles in the areas of human rights, labour, environment and anti-corruption.

Otsuka group Health Declaration established

2017 Otsuka group Health Declaration established
The Health Declaration was established to help create an environment that supports the mental and physical health of every employee and to promote various initiatives on employee health.

Otsuka Holdings signed statement of support for Women's Empowerment Principles (WEPs)

Otsuka Holdings announced declaration of Customer-centric Commitment

Otsuka Business Support Co., Ltd. established as a shared service company for Otsuka group companies

Otsuka Holdings named a "Nadeshiko Brand" in recognition of efforts in encouraging women's success in the workplace

Otsuka group of Companies acquired integrated certification for ISO 14001 environmental management system

Otsuka Pharmaceutical Co., Ltd. Established

Otsuka Pharmaceutical was established with the mission of becoming the “elder brother” of the future Otsuka group and of advancing development focusing on original technology. The company has created a global business based on the two mainstay businesses of pharmaceuticals, which are intended to restore the health of patients, and nutraceuticals, which are designed to maintain and enhance day-to-day wellbeing. Otsuka Pharmaceutical’s corporate philosophy—Otsuka-people creating new products for better health worldwide—is now the philosophy for the entire Otsuka group.
The calligraphy here is for the character so, from the Japanese word soshutsu, which means creation. It expresses Otsuka determination to create novel products and markets.

γ-oryzanol preparation Hi-z tablets launched

Although an in-licensed product, Otsuka Pharmaceutical succeeded in developing a new indication. Hi-z tablets supported the company’s pharmaceutical business until its new drug business took off.

Tokushima Factory opened

Otsuka Pharmaceutical in-licensed products from Italy-based Lepetit and started a manufacturing business for its own drugs.

Research center established at Tokushima Factory and new drug research commenced

Otsuka Pharmaceutical established its first research center for therapeutic drugs at the Tokushima Factory. The tree planted in front of the center to commemorate its opening has continued to grow for 40 years.

Thai Otsuka Pharmaceutical Co., Ltd. established. Representative office opened in the U.S.

Thai Otsuka Pharmaceutical Co., Ltd. was the Group’s first overseas operating company. Adopting plastic bottle technology that had been used in Japan from the outset, it has developed products beginning with basic I.V. solutions through to a range of clinical nutrition products.
Photograph: Building where the U.S. representative office was located

PT Otsuka Indonesia established

PT Otsuka Indonesia’s I.V. solution products enjoy a good reputation, and the company’s growth continues today to include pharmaceuticals and medical devices.

Otsuka Pharmaceutical Co., Ltd. makes equity investment in Japan Immunoresearch Laboratories Company Limited

Japan Immunoresearch Laboratories Company Limited carries out investigation into system devices for the treatment of refractory diseases, such as Adacolumn, as well as immune-diagnosis and treatment methods. The company changed its name to JIMRO Co., Ltd. in 2005. It is currently aiming to expand next-generation businesses as part of Otsuka Medical Devices Co., Ltd.

Union Giken Co., Ltd. (now Otsuka Electronics Co., Ltd.) joined Otsuka group

Union Giken Co., Ltd. was established in 1970 and changed its name to Otsuka Electronics Co., Ltd. in 1986. The company develops products ranging from components that include LED lamps and liquid crystal panels through to finished goods such as optical inspection and evaluation equipment and medical diagnostic and examination equipment.

Ion supply drink POCARI SWEAT launched

Development started in 1973 based on an idea of Akihiko Otsuka (the current chairman of Otsuka Holdings), who wondered if it were possible to make a “sweat drink.” He hoped to leverage the strength of the Otsuka group, which was a leading company in the field of I.V. solutions in Japan, to develop a beverage for quickly rehydrating and electrolytes (ions) in all everyday situations where people perspire.
Otsuka Pharmaceutical demonstrated that there was a huge market in Japan for ion supply drinks. POCARI SWEAT made a giant leap as a domestic beverage in 1995.

ß-blocker Mikelan and bronchodilator Meptin launched

Only ten years after applying for a patent for its first compound based on a carbostyril molecule (Mikelan), Otsuka Pharmaceutical managed to launch the second drug, thus becoming an original drug manufacturer.

China Otsuka Pharmaceutical Co., Ltd. Established

Otsuka was the first pharmaceutical company in the Western Block to enter China after the country’s so-called reform and opening up. As an equal joint venture with the Chinese government, China Otsuka Pharmaceutical Co., Ltd. has the honor of using “China” in its name.

POCARI SWEAT launched in Hong Kong and Taiwan

Calorie Mate balanced nutritional products launched

Calorie Mate opened the new field of balanced nutritional products. It contains a good balance of the five major nutrients, based on the liquid diet HINEX-R. Calorie Mate has remained the top brand in this field right up to the present day.

Hi-z Tower completed

The mural on the front of Hi-z Tower was created in ceramic panel based on an original by painter Taro Okamoto and named Inochi Odoru (Life Leaping) by Buddhist nun and writer Jakucho Setouchi. The building mainly houses the toxicity and metabolic research divisions and staff organization units. The tower was named after an in-licensed product that supported Otsuka group’s pharmaceuticals business for a long time before its own new drugs appeared.

Saga Research Institute opened

Saga Research Institute was opened as the base for nutraceuticals research. The institute aims to elucidate not average nutrition but individual nutrition for different lifestyles and situations, such as exercise.

Equity investment in U.S.-based Ridge Vineyards, Inc.

Ridge Vineyards owns a winery and its own vineyards in California in the U.S. Under the leadership of winemaking genius Paul Draper, the company consistently produces world-leading wines. In 2006, the company’s wines dominated the “Paris Tasting” with French wines, giving it the reputation of the world’s No.1.

Equity investment in South Korean-based Dong-A Foods (now Dong-A Otsuka Co., Ltd.)

Dong-A Foods was established in a 1979 spinoff of the food division of Dong-A Pharmaceutical Co., Ltd. The company develops original beverages for the South Korea market such as Demi Soda in addition to supplying beverages such as POCARI SWEAT. It is enjoying rapid growth thanks to the boom in health and sports drinks.

Human Resource Development Institute opened

The Human Resource Development Institute visualizes creativity, which is an important part of the philosophy of the Otsuka group, and develops human resources based on that philosophy. It is the company’s main assembly facility and is also opened to the community for concerts and other events. Art objects such as the Floating Stone created by Shiro Hayami, the Bent Giant Cedar created by Chuichi Fujii, and the Giant Tomato Trees created through a cultivation system designed by Shigeo Nozawa, stir thoughts of creativity in visitors.

Equity investment in US-based Pharmavite LLC

1Otsuka made an equity investment into a supplement manufacturer established in California in the U.S. in 1971. Pharmavite’s NatureMade has now grown into the leading vitamin and supplement brand in the U.S. This has contributed to the internationalization of the nutraceuticals business, which includes the introduction of NatureMade in Japan and delivery of SOYJOY from Japan.

Antiplatelet agent Pletaal launched

Launched with an indication for chronic arterial obstruction, which is a circulatory disorder of the peripheral blood vessels, Pletaal’s indications were later expanded to include the prevention of recurrence of cerebral infarction. Otsuka also developed tablets that dissolve in the mouth (OD tablets).

Dietary fiber-rich beverage FIBE-MINI launched

FIBE-MINI is a beverage that enables convenient consumption of dietary fiber, which tends to be lacking in people’s diets. In 1996 it was certified as a Food for Specified Health Use in Japan.

Aminoleban EN, an oral nutrient for liver failure patients, launched

Otsuka Pharmaceutical succeeded in developing Aminoleban, which had been approved as an injection for liver encephalopathy in 1984, into an oral nutrient for liver failure patients.

Tokushima Wajiki Factory opened

Conceived as a factory park, the grounds of Tokushima Wajiki Factory are open to the public. Effort is put into collaboration with the community, including the holding of an annual music festival. The factory produces pharmaceutical and nutraceutical products.

Otsuka America, Inc. and Otsuka America Pharmaceutical, Inc. established

Otsuka America, Inc. is the holding company for Otsuka Pharmaceutical’s U.S. business. Otsuka America Pharmaceutical, Inc. is responsible for the pharmaceuticals business.

Otsu Research Laboratories opened

Otsu Research Laboratories was opened as a base to develop cosmedics* for healthy skin. Today it includes the Otsu Nutraceuticals Research Institute.
* Cosmedics: cosmetics + medicine

Anti-gastric ulcer agent Mucosta launched

Mucosta was also approved in 1990 for the indication of gastritis and became the top brand among protective stomachic agents.

Equity investment in U.S.-based Crystal Geyser Water Company

Since 1994, Otsuka Beverage Co., Ltd. (now Otsuka Foods Co., Ltd.) has imported and sold Crystal Geyser Alpine Spring Water, which is produced at the Shasta plant of CG Roxane LLC.

theCALCIUM launched

theCALCIUM is a wafer food that provides the same rate of calcium absorption as milk. One packet contains 600 mg of calcium.

Energen launched

Energen is a sports drink intended to supply the energy needed for endurance exercise. It was developed to help the body efficiently turn fat into energy, while preserving the necessary energy for bursts of power.

Nature Made launched in Japan

Otsuka Pharmaceutical in-licensed Nature Made brand supplements from U.S.-based Pharmavite LLC. It introduced in Japan the concept of supplements that enable quality vitamins and minerals to be purchased easily.

Peptide-based enteral formula Twinline launched

Otsuka Pharmaceutical co-developed Twinline with Snow Brand Milk Products Co., Ltd., as a peptide-based enteral formula.

Otsuka Pharmaceutical Europe Ltd. Established

Otsuka Pharmaceutical Europe Ltd. is the holding company for the European pharmaceutical business of Otsuka Pharmaceutical Co., Ltd.

Tokushima Itano Factory opened

Surrounded by the nature of the Asan mountain range, the Tokushima Itano Factory is located near Asutamuland (a learning and park facility in Tokushima prefecture) and the home base of the Tokushima Vortis soccer team. The factory pursues a harmonious existence with the environment. It is also used as a place to hold environmental classes for community residents. It receives environment-related awards year after year. The factory produces pharmaceuticals and soy-based products.

Breath test agent UBIT launched

UBIT is a stable isotope urea formulation. It enables rapid, noninvasive testing for the presence of Helicobacter pylori in the stomach through a breath test given after taking UBIT orally. Otsuka Electronics simultaneously launched the analyzer UBiT-IR300 with UBIT.

Otsu Nutraceuticals Research Institute established in Shiga Prefecture

Antipsychotic ABILIFY launched in the U.S.

Otsuka Pharmaceutical co-developed and co-promoted ABILIFY with Bristol-Myers K.K. The product has grown to the point where it is sold in 60 countries and regions worldwide. It has gained a reputation as a global drug that represents the Otsuka group.

Soy beverage Sugoi Daizu launched

Sugoi Daizu was the first soy beverage in Japan to use whole soybeans including okara (known as soy fiber), which is ordinarily discarded when making soy milk, enabling consumption of soy protein and soy isoflavones as well as dietary fiber not contained in soymilk. It has a rich flavor that makes use of soy’s natural good taste.

EN Otsuka Pharmaceutical Co., Ltd. Established

EN Otsuka Pharmaceutical Co., Ltd. was established in a joint venture between Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., and Snow Brand Milk Products Co., Ltd. The company leverages its experience in the enteral nutrition field and strives to ensure quality, deliver stable supply and further enhance provision of information. It takes the initiative in new businesses, such as medical foods and food for the elderly.

Amino-Value launched

Containing endurance-boosting essential amino acids, Amino-Value is a branch chain amino acid (BCAA) beverage designed for use as a drink for exercise and other active situations. The product is intended for runners and other exercise enthusiasts, the numbers of which are increasing as people become more health conscious.

Otsuka Beijing Research Institute established

Otsuka Beijing Research Institute was established as the center for clinical development of pharmaceuticals from Otsuka Pharmaceutical Co., Ltd. in Asia.

Otsuka (China) Investment Co., Ltd. Established

Otsuka (China) Investment Co., Ltd. was established in Shanghai and is the holding company for the business of Otsuka Pharmaceutical Co. Ltd. in China.

The Wise Man’s Dining (a Food for Specified Health Use) launched

The Wise Man’s Dining suppresses the elevation of blood glucose levels after eating by slowing the absorption of sugars. Since 2012 it has been marketed as The Wise Man’s Dining - Double Support, a Food for Specified Health Use that holds down the absorption of both sugars and fat.

Cosmedics product InnerSignal launched

Discovering that Energy Signal AMP, a medicated active ingredient, has the effect of stimulating skin metabolism, Otsuka Pharmaceutical succeeded in making it into a product. It was the first item in the company’s line of cosmedics.

Equity investment in VV Food & Beverage Co., Ltd.

VV Food & Beverage is China’s leading manufacturer of soy milk. The Otsuka group aims to promote operational alliances, including provision of a range of technology and production know-how, to strengthen the business base for nutrition products in China. SOYJOY was launched in China the following year.

Soy bar SOYJOY launched

SOYJOY is a new type of nutritional food made from 100% soybean flour (containing no wheat) baked with a variety of wholesome ingredients. Developed as the first product based on the concept of “Soylution”—that soy can provide solutions to human health and environmental issues—SOYJOY was first launched in Japan, the U.S., and China and is currently being introduced in other countries and regions around the world.

Otsuka Pharmaceutical corporate symbol created

The large “O” represents the sky above and conveys the space for happy lifestyles that Otsuka delivers. The small “O” represents the energy of Otsuka that supports this happiness. With the establishment of Otsuka Holdings Co., Ltd. the following year, this became the Group’s corporate symbol.

UL・OS cosmedics for men launched

UL・OS is a skincare brand for men created out of Otsuka Pharmaceutical’s unique ideas and technology focused on cosmedics for skin health.

Equity investment in France-based ALMA S.A.

ALMA S.A., established in 1998, is a major in the European mineral water business. Among others, the company manufactures and sells CRISTALINE, France’s leading brand. Otsuka and ALMA are both promoting business expansion focused on the concept of “the century of water.”

Aquaretic launched in the U.S.

Otsuka Pharmaceutical launched in the U.S. the world’s first oral selective vasopressin (an antidiuretic hormone) V2-receptor antagonist Samsca.

Equity investment in France-based Nutrition & Sante SAS

Nutrition & Sante has developed its business in countries around Europe, primarily in France. The company manufactures and sells products using wheat germ and soy beans. It also sells SOYJOY in four European countries.

Oral vasopressin V2-receptor antagonist Samsca launched in Europe

Antiepileptic drug E Keppra launched

Otsuka Pharmaceutical launched E Keppra together with UCB Japan Co., Ltd., in Japan, where it has become the top brand in epileptic treatment.

Carbonated soy beverage SOYSH launched

Otsuka Pharmaceutical developed SOYSH based on the Soylution concept. It is a carbonated soy beverage without the distinctive soymilk aftertaste of soy and a refreshing quality provided by carbonation. SOYSH will spread the appeal of soy across generational lines.

Business tie-up agreement signed with H. Lundbeck A/S in the central nervous system field

Otsuka Pharmaceutical entered into a global alliance agreement with Denmark-based H. Lundbeck in order to further enhance Otsuka’s presence in the central nervous system field, which has become a key part of the company’s pharmaceuticals business.

Otsuka Pharmaceutical opens BeanStalk Kids Center, a day care center located inside the Otsuka office building in Tokushima

A day care center was established inside Otsuka’s office building in Tokushima to support diversity and work-life balance. Taiho Pharmaceutical went on to open the Sukusuku Nursery in Tsukuba in 2013. Otsuka pharmaceutical also opened BeanStalk Kids Center Osaka in 2014.

Heartful Kawauchi Co., Ltd. Established

Heartful Kawauchi Co., Ltd. was established as a special subsidiary company to promote the employment of people with disabilities. The company aims to create a work-friendly environment for people with disabilities, based on the key concepts of “independence, creativity, proof through execution, dreams, and affection.”

Healthy soy snack SoyCarat launched

SoyCarat is a healthy soy snack developed based on the Soylution concept. SoyCarat provides the nutrition of soy with the enjoyment of a fun rattling sound made when shaken. Since it is baked and not fried, SoyCarat is also low in calories.

POCARI SWEAT ION WATER launched

ION WATER is new version of POCARI SWEAT developed over a period of six years in pursuit of a light sweetness and refreshing taste suited to modern society.

Omugi Seikatsu healthy breakfast products launched

The scientific community has been taking notice of the benefits of barley (omugi), which is rich in barley beta-glucans, a type of water-soluble fiber. Otsuka Pharmaceutical launched Omugi Seikatsu (which means “barley lifestyle”) in a line of five products in three categories.

Antipsychotic ABILIFY MAINTENA launched in the US

ABILIFY MAINTENA is a new form of ABILIFY, an intramuscular (IM) once-monthly injectable formulation indicated for the treatment for schizophrenia.

Equity investment in Astex Pharmaceuticals.

Astex is known as a leading company in fragment drug discovery and has a clinical development division in California, USA and a drug discovery laboratory in Cambridge, UK. Otsuka Pharmaceutical expands its oncology portfolio and strengthen its drug discovery research in the area of central nervous system.

Additional indication approved for Samsca/JINARC for the treatment of ADPKD in Japan

This is the world’s first treatment that slows the progression of autosomal dominant polycystic kidney disease (ADPKD), a genetic disease that causes cysts to develop and enlarge the kidneys.

EQUELLE, equol-containing food derived from soybeans, launched in Japan

Equol is produced when daidzein, a component of soy isoflavones, is metabolized by intestinal bacteria. This product is the result of 18 years of work at the Saga Nutraceuticals Research Institute.

Antituberculosis? drug DELTYBA launched in Europe, Japan and South Korea

DELTYBA was launched as one of the world’s first new antituberculosis drug in about 50 years. It was Japan’s only multidrug-resistant tuberculosis treatment at that time.

Otsuka Pharmaceutical and Otsuka Foods establish Otsuka Wellness Vending Co., Ltd.

Otsuka Pharmaceutical and Otsuka Foods established a new company to run the vending machine business.

Equity investment in US-based Avanir Pharmaceuticals Inc.

Avanir Pharmaceuticals is a biopharmaceutical venture company that developed and launched NUEDEXTA, the world’s first and only treatment for the neurologic disease pseudobulbar affect (PBA). This full-scale entry into the neurologic field accelerates Otsuka’s expansion strategy in the field of central nervous system diseases.

Antipsychotic REXULTI launched in the US

REXULTI, a new antipsychotic treatment discovered by Otsuka Pharmaceutical, is a novel serotonin-dopamine activity modulator (SDAM) that shows high affinity for the dopamine and serotonin receptors. It is indicated for an adjunctive therapy for the treatment of adults with major depressive disorder and as a treatment for adults with schizophrenia.

RIKEN CDB-Otsuka Pharmaceutical Collaboration Center opened

RIKEN CDB-Otsuka Pharmaceutical Collaboration Center was opened inside the RIKEN Center for Developmental Biology (RIKEN CDB). The two centers will collaborate on innovative research, aiming to discover disease mechanisms based on discovery and regenerative research.

Anticancer agent tyrosine kinase inhibitor ICLUSIG launched in Japan

This tyrosine kinase inhibitor, developed by ARIAD Pharmaceuticals, was marketed in Japan as an oral treatment for chronic myeloid leukemia and Philadelphia Chromosome-positive acute lymphoblastic leukemia.

Global licensing agreement concluded with Akebia Therapeutics, Inc. for renal anemia drug Vadadustat

BODYMAINTE Jelly, a conditioning food, launched in Japan

This food contains the lactic acid bacteria B240 (a strain licensed to Otsuka Pharmaceutical), BCAA+Arginine and whey protein to help prevent deterioration of physical condition under rigorous training regimens.

Equity investment in North America-based Daiya Foods Inc.

Daiya Foods is a fast-growing plant-based foods company in Canada. The company produces dairy substitutes, dressings and desserts made of plant-derived ingredients.

Acquired US Bioventure Company, Neurovance, Inc.

Expansion of central nervous system portfolio

Licensing agreement signed with Teva Pharmaceutical Industries, Ltd. for development and commercialization of prophylactic migraine drug candidate Fremanezumab (TEV-48125) in Japan

Licensing agreement signed with R-Pharm JSC to commercialize Deltyba™ (Delamanid) in the Russian Federation and Commonwealth of Independent States

License agreement concluded with Viatris (formerly Mylan) for commercialization of Delamanid for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in high-burden countries

EQUELLE launched in US

Support women's health

Otsuka Nutraceutical (Thailand) Ltd. established

New subsidiary to focus on health beverage and food sector

Quick Navi-Flu2 Influenza Diagnostic Kit launched in Japan

Otsuka Pharmaceuticals (Singapore) Pte. Ltd. established.

New marketing subsidiary of pharmaceutical products

New antipsychotic drug REXULTI launched in Japan

ORONAMIN C DRINK debuted in Indonesia

Acquired US-based Visterra Inc.

Hierotope®platform enables design and engineering of next-generation antibody-based therapies

JYNARQUE™ approved by U.S. FDA as the first treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

Otsuka Myanmar Company Ltd. established.

New subsidiary to focus on health beverage sector

Tokushima Mima Factory opened

Selincro, therapeutic drug treatment to reduce alcohol consumption, launched in Japan

First drug approved in Japan to reduce alcohol consumption in alcohol-dependent patients

POCARI SWEAT marketing won Grand Prix at Japan Marketing Awards

Otsuka Nutraceutical Mexico S.A. de C.V. established

New subsidiary to focus on health beverage sector

Otsuka Pharmaceuticals (Malaysia) Sdn. Bhd. Established

New marketing subsidiary of pharmaceutical products

Busaburo Otsuka founds Otsuka Seiyaku Kogyo-bu (Otsuka Pharmaceutical)

The first office and research laboratory building, which still stands on the grounds of Otsuka Pharmaceutical Factory, in Naruto, Tokushima Prefecture. Started manufacture and distribution of magnesium carbonate in compliance with the Japanese Pharmacopoeia from the liquid (called “bittern”) that is left over after taking the salt out of salt pans. Company renamed Otsuka Pharmaceutical Factory in 1940.

Manufacture and distribution of injection solutions started

Pharmaceuticals business entered after the war. Licenses obtained to manufacture the following injection solutions in compliance with the Japanese Pharmacopoeia: Ringer solution, Locke solution, sodium chloride injection, calcium chloride injection, and calcium bromide.

MEYLON Injection, a 7% sodium bicarbonate injection solution, launched

Acidosis treatment—a 7% sodium bicarbonate injection solution. One of the company’s hit products in its early years.

Hydrazide Otsuka, an antitubercular drug, launched

Succeded in making a drug containing isonicotinic acid hydrazide (INAH) and produced it in-house using hydrazine and other raw materials made by Otsuka Chemical.

Oronine Ointment antiseptic for home uses launched

Atiseptic for home uses. The Otsuka group’s first OTC pharmaceutical product. In-licensed raw material from the US-based Oronite Chemical Company and successfully co-developed with the University of Tokushima. Groundbreaking marketing methods such as the use of loudspeaker vans, the provision of large numbers of free samples, and the use of direct mail were adopted. Formulation continued to be improved, making Oronine Ointment a long-seller.

Pan-Amin, an essential amino acid injection, and Pan-Amin S, a hypertonic injection of essential amino acids, launched

Launched as amino acid supplements for times of malnutrition. Underpinned growth and helped to establish the I.V. solutions business.

KN solution series (electrolyte solutions) launched

KN solution series (electrolyte solutions) launched and a solid position established as a maintenance I.V. solution.

Lactec Injection, a Lactated Ringer's solution launched

Became the mainstream extracellular fluid replacement solution in Japan.

Introduced a plastic bottle for I.V. solutions

Japan’s first plastic bottle for I.V. solutions manufactured. Initially introduced polyethylene containers from Switzerland-based Hausmann Laboratories, Inc., but the transparency was inadequate, and so reintroduced a polypropylene product from US-based Hercules, Inc.

MARTOS Injection 10%, a disaccharide I.V. solution, launched

Japan’s first disaccharide I.V. solution.

Kushiro Factory starts operations

Located in the town of Onbetsu outside of the city of Kushiro, Hokkaido, the factory was built to supply I.V. solutions to areas north of the Kanto region.

POTACOL R Injection, a lactated Ringer's solution containing maltose, launched

This lactated Ringer's solution containing maltose became the mainstream such product containing glucose.

PLAS-AMINO Injection, an I.V. solution containing glucose and amino acids, launched

A groundbreaking, first of its kind injection in Japan with glucose and amino acids all in one package.

AMINOLEBAN Injection for treatment of hepatic encephalopathy in patients with liver impairment launched

A treatment for hepatic encephalopathy in patients with liver impairment. A pioneer for the company’s diverse I.V. solutions for various specific clinical conditions.

Otsuka Techno Corporation established

The company’s head office and plant are located in Tokushima Prefecture. The company manufactures and sells medical plastic container components and precision molding products.

TRIPAREN Injection, a TPN electrolyte solution, launched

A total parenteral nutrition (TPN) electrolyte solution containing complex sugars (GFX).

AMIPAREN Injection, a total amino acid solution, launched

A total amino acid solution with new amino acid composition and TEO-standard formulation. Developed for combination with TRIPAREN.

Matsushige Factory starts operations

Manufactures products such as injection drugs in plastic ampules, various I.V. solutions in soft bags, and the world’s first dual-chamber bag kits for aseptic delivery of antibiotic solutions.

AMINOTRIPA Injection, a TPN solution in a dual-chamber bag, launched

A dual-chamber bag product that combines TRIPAREN and AMIPAREN, developed for aseptic preparation. Reduces preparation time.

AMINOFLUID Injection, a glucose-added amino acid solution with electrolytes for PPN packaged in a dual-chamber bag, launched

Japan’s first glucose-added amino acid solution with electrolytes for PPN packaged in a dual-chamber bag.

KIDMIN Injection, an amino acid injection for renal failure, launched

An amino acid injection for renal failure with an improved formulation developed. Obtained one of the few formulation patents for I.V. solutions.

Cefazolin Sodium Injection 1g Bag Otsuka, an antibiotic kit product, launched

Stores the powdered antibiotic and the dissolving solution in separate chambers, which can be mixed instantaneously with a single press at the time of use. Attention paid to ease of handling in the field, storage, and disposal.
The world's first antibiotic kit product with antibiotic and isotonic sodium chloride solution in separate chambers, which can be prepared with a single press.

RACOL, a semi-digested enteral nutrient, launched

Co-developed with Snow Brand Milk Products Co., Ltd., as an enteral nutrient suited to the Japanese.

Physio 140 Injection, an acetated Ringer's solution with 1% glucose, launched

Set a new concept in extracellular fluid expanders.

OS-1, an oral rehydration solution, launched

A food for the sick, perfect for replenishing and maintaining hydration and electrolytes in persons in a state of mild to moderate dehydration. Available nationwide since 2005.

EN Otsuka Pharmaceutical Co., Ltd. Established

EN Otsuka Pharmaceutical Co., Ltd. was established in a joint venture between Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., and Snow Brand Milk Products Co., Ltd. The company leverages its experience in the enteral nutrition field and strives to ensure quality, deliver stable supply and further enhance provision of information. It takes the initiative in new businesses, such as medical foods and food for the elderly.

NEOPAREN Injection, a formulation containing glucose, electrolytes, amino acids, and multiple vitamins for TPN in a triple-chamber bag, launched

Japan's first triple-chamber bag.

BFLUID Injection, a glucose-added electrolyte and amino acid solution with vitamin B1, launched

As the successor to AMINOFLUID, contains vitamin B1, which is needed in glucose metabolism. This became a mainstream product in the field of peripheral I.V. nutritional solutions

ARTCEREB Irrigation and Perfusion Solution for Cerebrospinal Surgery launched

The world’s first irrigation and perfusion solution for cerebrospinal surgery.

ELNEOPA Injection, a TPN formulation containing glucose, electrolytes, amino acids, multiple vitamins and trace elements, launched

The world's first TPN formulation containing glucose, electrolytes, amino acids, multiple vitamins, and trace elements. Supplied in a four-chamber bag, the pinnacle of TPN products.

Information Center for Infusion Therapy and Products opened

Exhibits trends in the I.V. solutions business. Also serves as a research organization for academic product information and a facility for training in infusion therapy.

BICANATE Injection, a bicarbonated Ringer's solution, launched

A bicarbonated Ringer's solution, achieving a formulation combined with bicarbonic acid, which had been difficult previously.

EN Otsuka Pharmaceutical Co., Ltd. launches iEat in Japan

This is a food for supporting patient recovery; unique technology makes it easy to chew while still preserving the shape and flavor of the food and ingredients.

Sodium Phosphate Corrective Injection launched

A phosphate corrective injection in which attention was paid to preventing medical accidents.

RACOL-NF Liquid for Enteral Use, a low residual diet preparation (for feeding tube and oral administration), and Twinline-NF Liquid for Enteral Use, an elemental diet preparation, launched

Products of which the amount of phytonadione (vitamin K1) is lower than that of Twinline Liquid for Enteral Use and RACOL Liquid for Enteral Use, in consideration of the administration to the patients using warfarin.

Voluven 6% solution for infusion launched

A plasma substitute used to maintain adequate circulating blood volume.

Equity investment in Claris Otsuka Limited

Otsuka agreed to make a joint venture investment with Mitsui & Co., Ltd. in a new company in the I.V. solution business established by Claris Lifesciences Limited, a major I.V. solution and medical goods manufacturer and seller in India, with a view to expanding the I.V. solution business in India.

Hine E-Gel, a concentrated liquid diet, launched

A concentrated liquid diet whose physical properties change to gel depending on decreasing pH.

Povidone Iodine Solution 10% Antiseptic Applicator Otsuka 10 mL/25 mL launched

Japan's first applicator-type antiseptic (antiseptic combined with applicator) whose applicator has been improved from that generally used in medical institutes in the U.S. with our unique technology.

RACOL-NF Semi Solid for Enteral Use launched

Japan's first semi-solid enteral nutrition formula as an enteral nutrition product in Japan.

Processlead, a chew and swallow managing food, launched

A chew and swallow managing food that forms an easy-to-swallow mass with an appropriate size and shape upon chewing, which supports oral intake.

Egypt Otsuka Pharmaceutical acquires Ateco Pharma Egypt

Egypt Otsuka Pharmaceutical acquired 100% ownership of Ateco Pharma Egypt, an Egyptian IV solutions manufacturing and distribution company. Ateco will be renamed “Otsuka Ateco Pharma Egypt (Ahmed Zaghloul & Partners) Limited Partnership”

Olanedine Antiseptic Solution 1.5% (200 mL) and Olanedine Solution 1.5% Antiseptic Applicator 10 mL/25 mL launched

A novel biguanide-based antiseptic whose active ingredient is olanexidine gluconate. It is a new antiseptic for external use, developed in Japan for the first time in 50 years.

ELNEOPA-NF No.1/No.2 Injection, a TPN formulation containing glucose, electrolytes, amino acids, multiple vitamins, and trace elements, launched

New products with the formula revised from that of ELNEOPA No. 1/No. 2 Injection, referring to the FDA formulation, etc. widely used abroad.

REHADAYS to help make body strong launched

A beverage containing necessary nutrients to help to make the body strong during exercise and rehabilitation.

ENORAS Liquid for Enteral Use (for feeding tube and oral administration) launched

Cellstor-S, cell suspension and preservation solution, and Cellstor-W Cell, cell wash and preservation solution launched

Hine E-Gel LC, concentrated liquid diet product, launched

Oral care gel (medicated toothpaste) HINORA (quasi-drug) and oral moisture gel HINORA Moisture Gel (oral cosmetic) launched

VISCOCLEAR, gel to secure the visual field that is used for the endoscope for natural opening, launched

ENEFLUID Injection launched―an amino acid, glucose, electrolyte, fat, and water-soluble vitamin injection

Taiho Pharmaceutical Co., Ltd. Established

The name Taiho derives from a passage in the first chapter (“A Happy Excursion”) of a Taoist classic written by the ancient Chinese philosopher Zhuangzi, which describes a giant bird with a wingspan like clouds filling the sky. In Japanese, the bird’s name is pronounced Taiho. The company was established with investments from 49 distributors around the country.

Solcoseryl injection, a tissue respiration stimulating agent, launched

A tissue respiration stimulating agent introduced from Switzerland. At first it was used as a treatment for peptic ulcers and later (and still today) for cerebrovascular disease and skin ulcers.

Vitamin tonic Tiovita Drink launched

Tiovita Drink, a vitamin tonic, was created in the midst of a boom in Japan for liver tonics and became Taiho’s first OTC product.

Herbal crude drug Taiho Digestive Oral Solution launched

The product became a hit as a drug in an ampule. After numerous improvements it later became Solmack, which is now the top brand in fluid digestive medicines.

Deer antler velvet extract Pantocrin injection launched

Pantocrin injection was introduced from the former Soviet Union as a treatment for essential hypotension and later grabbed the spotlight as a drug to ameliorate general malaise in whiplash.

Taiho’s first research building completed

This building was constructed on the premises of Otsuka Pharmaceutical Factory’s head office in Naruto.

Seventh plant (lyophilized formulation plant) completed

This Taiho plant was constructed at the Imagire Industrial Park in Tokushima.

Anticancer drug Futraful launched

Futraful created the new domain of adjuvant chemotherapy in cancer treatment, launching a whole new field. Thanks to its oral administration, it also made outpatient therapy with an anticancer drug possible.

Herbal digestive medicine Solmack launched

Taiho markets Solmack as an herbal fluid digestive medicine that helps with the queasiness of a hangover.

GLP-compliant research facilities completed in Tokushima

Taiho constructed the Tokushima Research and Development Laboratory and Safety Laboratory.

Anticancer agent UFT launched

UFT was the first formulation made based on the biochemical modulation concept. It is the successor drug to Futraful, researched and developed in search of even more effective and safer anticancer effects.

Kodama Laboratory established

Kodama Laboratory was established in the city of Kodama, Saitama as a center for research in synthesis and drug discovery.

Synphar Laboratory established in Canada

Synphar Laboratory was established in Alberta Canada as Taiho’s first research facility outside Japan. It conducts research into β-lactamase inhibitors and antiphlogistic analgesics.

Herzer, a transdermal patch for treating heart disease, launched

Herzer is a nitroglycerin transdermal tape.

Otsuka group Seminar and Training Center, Drug Discovery Center, and Computer Center opened

The centers were established in the city of Hanno, Saitama. They are also used as a training center of Otsuka group.

BUP-4 tablet, a therapeutic agent for urinary incontinence and frequent urination, launched

Taiho entered the urology field with this therapeutic agent for urinary incontinence and frequent urination.

Anticancer agent TS-1 capsule launched

TS-1 capsule was approved for the indication of gastric cancer through fast-track review by Japan’s Ministry of Welfare.Since 2010 it has been the standard treatment for advanced and recurrent gastric cancer.

Harncare Oral Solution, an herbal crude drug and drug for mild incontinence and frequent urination, launched

An herbal OTC product targeting alleviation of mild incontinence and frequent urination.

Taiho Pharma U.S.A., Inc. established

The company was established in New Jersey, U.S. as the center for the U.S. cancer treatment business.

Reduced folic acid formulation UZEL tablet launched

The drug’s anticancer effects against colorectal cancer are enhanced in combination with UTF. In June 2005, this combination therapy was included in the Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2005 for the Treatment of Colorectal Cancer as a treatment that could be given orally, among standard chemotherapeutic regimens.

Tsukuba Research Center established

Integrated with the Hanno Research Center, the Tsukuba Research Center carries out drug discovery research and preclinical studies.

5-HT3 receptor antagonist Aloxi launched

An antiemetic with a plasma half life of approximately 40 hours that is effective against acute and late-onset nausea and vomiting.

Anticancer agent Abraxane launched

Used to treat breast cancer as a new paclitaxel formulation.

Otsuka Pharmaceutical opens BeanStalk Kids Center, a day care center located inside the Otsuka office building in Tokushima

A day care center was established inside Otsuka’s office building in Tokushima to support diversity and work-life balance. Taiho Pharmaceutical went on to open the Sukusuku Nursery in Tsukuba in 2013. Otsuka pharmaceutical also opened BeanStalk Kids Center Osaka in 2014.

Kitajima Plant completed

The Kitajima Plant was constructed as a manufacturing base for global products.

Anticancer drug LONSURF combination tablet T15/T20 launched in Japan

Taiho Pharmaceutical discovered this antineoplastic nucleoside antitumor agent, and launched it with an indication of unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

LONSURF launched in the US

LONSURF is an oral nucleoside antitumor agent that was Taiho's first product to obtain FDA approval.

Herbal digestive support Solmack 5 launched in Japan

The first pre-meal drink in the Solmack series was released.

Taiho Pharmaceutical establishes US-based Taiho Ventures, LLC.

Taiho Ventures, LLC will invest in promising start-up companies in and outside Japan that are researching and developing innovative new drugs in the field of oncology.

Bilanoa Tablets 20 mg, an oral anti-allergy drug, launched in Japan

Outside Japan, this drug has been approved in over 100 countries and regions* for the treatment of allergic rhinitis and urticaria. It is co-marketed in Japan with Meiji Seika Pharma Co., Ltd.
*Taiho Pharmaceutical holds the development and marketing rights in Japan.

Tiovita 3000 launched in Hong Kong

LONSURF obtained marketing approval in Europe

Taiho Pharma Canada, Inc. established in Canada

LONSURF obtained marketing approval in Canada

Taiho Innovations, LLC. established in Japan

TAIHO ONCOLOGY EUROPE GMBH established in Switzerland

Otsuka Warehouse Co., Ltd. Established

Otsuka Warehouse Co., Ltd. has developed warehousing and transportation businesses focused mostly on meeting the needs of the Otsuka group.

Otsuka Warehouse Co., Ltd. made equity investment in Nagahama Packaging Co., Ltd. (now Otsuka Packaging Industries Co., Ltd.)

Nagahama Paper Store was established in 1912 and changed its name to Otsuka Packaging Industries Co., Ltd. in 1978. The company works as a packaging manufacturer that can provide the planning capabilities to make products appear even more attractive as well as packaging of consistent quality.

Otsuka Warehouse promotes joint logistics system.

Otsuka Warehouse established a shared pladform system to deliver other companies' products (pharmaceuticals, beverages, foods and other products for everyday use). The service is an extension of Otsuka Warehouse's main activity to deliver Otsuka products.

Otsuka Warehouse won a Logistics Award Management Innovation Award

Otsuka Warehouse was awarded this prize by the Japan Institute of Logistics in recognition of utilizing the scheme of shared platform and providing positive impact on manufactures for their logistics needs.

Otsuka Warehouse introduces an ID warehouse

Important data (ID) is derived from past data to set optimal algorithms and create optimal work plans. ID transport was also introduced in 2015.

Otsuka Warehouse wins fiscal 2015 Logistics Grand Prize

Otsuka Warehouse was awarded this prize by the Japan Institute of Logistics Systems in recognition of its development of a system to resolve the shortage of drivers and trucks plaguing the logistics industry. Otsuka Warehouse won this award for a second time in 2016.

Otsuka Warehouse completes West Japan Logistics Center, the first warehouse dedicated to medical products

This center, which is compliant with the business continuity plan, is being operated to develop a more robust system for the stable supply of pharmaceuticals.

Otsuka Chemical and Medical Products, Inc., established

The organic chemical division was spun off from Otsuka Pharmaceutical Factory.
Later, the company developed businesses such a hydrazine-related business including foaming agents, a fine chemical business including intermediate materials for pharmaceuticals, and a materials business handling titanate compounds and engineering plastic composites.

Polymerization catalyst AIBN launched

Polymerization catalyst azobisisobutyronitrile (AIBN) was the company’s first internationally successful product. Today, its successor product is used in the manufacture of carbon fiber.

Uniform AZ foaming agent launched

A plastic foaming agent that is a hydrazine derivative. It is used in synthetic resin and rubber helps to save weight, as it increases a material’s heat insulating properties, sound insulation, flexibility, and decorative nature. It is also used in a variety of fields, ranging from industrial goods, civil engineering and building materials, agricultural and fisheries goods to sports equipment and everyday sundries.

ORONAMIN C DRINK launched

It could not be sold through the pharmacy route as a quasi-drug since it was a carbonated drink, so Otsuka Chemical decided to utilize Otsuka Pharmaceutical’s sales routes through general retail shops. Today it has become Japan's best-selling, longest-selling beverage, with total sales of 30 billion bottles.

Imagire Plant opened

A hydrazine manufacturing plant and Bon Curry plant were constructed in Imagire Industrial Park in Kawauchi-cho, Tokushima.

Rust-preventive agent Shadan launched

Used in such applications as skin pass agents for steel plate and coolants for diesel railcars.

Otsuka Ohmi Ceramics Co., Ltd. Established

Otsuka Ohmi Ceramics Co., Ltd. manufactures and sells large art ceramic boards and a variety of ceramic materials utilizing its own original technologies.

Flavor enhancer Maltol launched

A food additive that helps to balance (mix) the components of flavorings. It is included in many foods and beverages that use sweet flavorings. Otsuka Chemical was the first in the world to successfully industrialize organic electrolytic synthesis technology in an organic solvent. It marked the company’s entry into the fine chemicals business.

Potassium titanate fiber TISMO launched

The first in Otsuka Chemical’s series of potassium titanate materials. Possessing many features such as high intensity, high rigidity, and high aspect ratio, it was initially used in bumpers for luxury cars and later in brake discs and as a raw material in composites with plastic.

Functional plastic composite POTICON launched

Following up on its success in developing TISMO, the company went on to create POTICON, a composite of plastic with microscopic potassium titanate fiber made possible by proprietary technology. POTICON dramatically improved machining accuracy, which had been a weakness of plastics, and became an essential material in such things as microscopic gears.

Korea Otsuka Co., Ltd. (now KOC Co., Ltd.) established

The company manufactures and sells hydrazine hydrate and was the first overseas production and sales center for Otsuka Chemical Co., Ltd. The company has since been pursuing overseas expansion, including equity investment in Spain-based Hebron S.A. in 1989.

Otsuka Beverage Co., Ltd. Established

Otsuka Beverage Co., Ltd. introduced the market to such drinks as Java Tea. It promoted the Group’s non-alcoholic beverage business in a tie-up with Nestle Japan Limited. It subsequently merged with Otsuka Foods Co., Ltd.

Antibiotic intermediate GCLE launched

A core product in the fine chemicals business for the manufacture of pharmaceutical intermediates. Otsuka Chemical was the first in the world to successfully manufacture this cephalosporin antibiotic intermediate using skeletal transformation of penicillin.

Production of tazobactam intermediate YTR830H started

Achieved GMP bulk drug mass production for this β-lactamase inhibitor. At present the drug has been transferred outside the Otsuka group. This was the world’s first computer-controlled GMP plant.

AgriBest Co., Ltd. Established

Produces and provides quality fruit tomatoes and other crops using the latest agricultural technology.

Production of the flaky potassium titanate material TERRACESS started

Developed flaky potassium titanate material as a raw material for disc brake pads.

Otsuka-MGC Chemical Company, Inc. established.

The business company for hydrazine hydrate established by Otsuka Chemical Co., Ltd., and Mitsubishi Gas Chemical Co., Ltd., as an independent hydrazine business.

Zhangjiagang Otsuka Chemical Co., Ltd. Established

Zhangjiagang Otsuka Chemical Co., Ltd. was established in Jiangsu Province, China. It manufactures and sells TERRACESS, a flaky titanate material, and resin composites.

Acquisition of Ito life Science Co., Ltd
(present ILS Inc.)

This company runs a peptide business, pharmaceutical business, and functional foods business.

Otsuka Ohmi Ceramics Co., Ltd. begins reproducing the images from the Kitora Tomb Stone Chamber

Reproduction of the images from the Kitora Tomb Stone Chamber using ceramic boards began at the request of the Agency for Cultural Affairs.

Functional polymer TERPLUS developed

A high performance polymer made using the new living radical polymerization method (TERP method).

Capacitor electrolyte Q-CHARGE launched

An electrolyte for electric double layer capacitors. It is used in the field of industrial equipment and in automotive applications.

Otsuka Chemical establishes Otsuka Chemical America, Inc.

Otsuka Chemical America, Inc. is Otsuka Chemical’s base in the Americas.

Otsuka Chemical acquires Higashiyama Film Co., Ltd.

Otsuka Chemical applied TERPLUS, the advanced polymer product synthesized by its living radical polymerization technology, to adhesion technology made possible by Higashiyama Film’s coating technology. Together with the existing management of Higashiyama Film Co., Ltd., Otsuka Chemical aims to provide higher quality and value-added products and to strengthen the business foundation.

Otsuka Pharmaceutical and Otsuka Foods establish Otsuka Wellness Vending Co., Ltd.

Otsuka Pharmaceutical and Otsuka Foods established a new company to run the vending machine business.

Otsuka Chemical establishes Otsuka Chemical (Shanghai) Co., Ltd.

Otsuka Chemical (Shanghai) Co., Ltd. markets the products of the Otsuka Chemical and Zhangjagang Otsuka Chemical in China.

Otsuka Chemical India Pvt. Ltd. expanded GCLE Production Capacity

Peptide Business transferred in absorption-type split

The part of the Cefixime Business succeeded from Astellas Pharma

Established Shonan Lab. in Fujisawa-City,Kanagawa.

Otsuka Foods Industry Co., Ltd. Established
(currently Otsuka Foods Co., Ltd.)

Otsuka Foods Industry Co., Ltd. started with equity investment in CBC Foods Industry Co., Ltd.

Bon Curry launched

The company launched the world’s first commercial retort food product, which was inspired by the ready-to-eat meals used by the military featured in foreign magazines. For initial presales in the Hanshin area, the product was packed in a semi-transparent pouch. This was changed to an aluminum pouch for the nationwide launch the following year, and Bon Curry pioneered a diverse range of retort food products.

Bon Curry Gold launched

A new product lavished with spices and fruit was launched, taking note of the changing tastes of Japanese consumers.

Kushiro Factory established

Otsuka Food’s Kushiro Factory, located adjacent to Otsuka Pharmaceutical Factory’s Kushiro Factory, is set in an environment with abundant nature and good quality water. It manufactures its own products and contract-manufactures Otsuka group products such as ORONAMIN C DRINK and POCARI SWEAT.

Biwako Research Institute established

Biwako Research Institute seeks to develop products based on the themes of “flavor, safety, peace of mind and health.”

Sherbet drink Sherbe launched

This frozen desert with the texture of sherbet, which is mixed with milk, caused a new sensation.

Arukimendesu launched with sauce and noodles packaged separately

The dried noodles and sauce were packaged separately, creating a stir because of the innovation in product style and taste.

Shiga Factory established

The Shiga Factory manufactures a range of its own products as well as group products such as POCARI SWEAT.

Micro Magic launched

The potato fries are processed using a special technique which keeps them crisp even when microwaved.

Otsuka Beverage Co., Ltd. Established

Otsuka Beverage Co., Ltd. introduced the market to such drinks as Java Tea. It promoted the Group’s non-alcoholic beverage business in a tie-up with Nestle Japan Limited. It subsequently merged with Otsuka Foods Co., Ltd.

Otsuka Beverage launched Sinvino Java Tea Straight

Three Otsuka group companies, Otsuka Pharmaceutical, Otsuka Foods, and Otsuka Chemical, established Otsuka Beverage (now Otsuka Foods) with the intention of making a full-scale entry into the non-alcoholic beverage and food markets. The same year, sugar-free Sinvino Java Tea Straight, made from Indonesian tea, was launched.

Forty’s Series launched

Based on the concept of “Giving our bodies what they need and eliminating excess,” the Forties Series offers meals that take account of the bodily changes that come with age, using ingredients such as soy meat and soy oligosaccharides that are developed in-house.

Ridge wines launched in Japan

In 1986, Otsuka Pharmaceutical took an equity stake in Ridge Vineyards, a distinguished winery that is a California icon. Otsuka Foods commenced sales of Ridge wines in Japan in 1991, establishing Ridge as a high-end brand for discerning customers.

A! Aretabeyo launched

This was an epoch-making product, allowing curry and rice to be heated in a microwave at the same time. It is manufactured using a pressured, microwave heating treatment.

500ml Crystal Geyser launched

Crystal Geyser is a soft mineral water, which suits the tastes of Japanese consumers, sourced from Mount Shasta in California in the US.

Semi-sparkling vitamin beverage MATCH launched

MATCH is a carbonated vitamin drink with a harmonious blend of vitamins and minerals. The gentle carbonation produces a sweeter, cleaner aftertaste.

Mannan Hikari launched

Mannan Hikari meals have the texture of rice and are made from ingredients that include refined konnyaku flour. Mixed with rice, they facilitate calorie control and dietary fiber intake. Mannan Hikari was a rebranding of Mannan Komachi, which was launched in 1998.

Dried vegetables e.v. Yasai launched

e.v. Yasai was a new line of frozen vegetables manufactured using the soft-freeze method.

New and improved Bon Curry launched

The new and improved Bon Curry takes two minutes to heat in the microwave while still in the box.

Crystal Geyser Sparkling Water Lemon Flavor launched

Crystal Geyser Sparkling Water Lemon Flavor is a calorie-free, sparkling water beverage made from natural mineral water.

"Ginza Rokusantei" Series, launched, bringing the taste of a traditional Japanese restaurant to the home

ReSOLA 10-grain porridge for clean eating launched

Based on the concept of “Start clean eating,” the goal of ReSOLA was to make it easier to include natural ingredients, principally cereals, in the diet.

Otsuka Chilled Foods Co., Ltd. Established

Otsuka Chilled Foods Co., Ltd. integrated the Otsuka group’s chilled food business.

Bon Curry Neo launched

Otsuka Food works a labor of love to create a Bon Curry using Japanese-made ingredients. The new and improved Bon Curry takes two minutes to heat in the microwave while still in the box.

My Size launched

Otsuka Foods developed the My Size series with the concept of “a meal that’s just the right size,” creating retort food products with moderate calories and mass that allow consumers to easily see the serving size.

Bon Curry Gold launched

45 years after it first appeared on the market, this new and improved Bon Curry is heated in the microwave while still in the box. This is a new-age retort food product that is simple and convenient, with a delicious flavor that draws out the aroma of the spices, and also features safety, peace of mind and is eco-friendly.

Shizen Shokkan CHiA series launched in Japan

The second line of products in the Shizen Shokkan series was launched. They are made in small batches and are rich in a range of nutrients. They are made with chia seeds, a valuable ingredient that ancient Aztec kings monopolized.

Berry MATCH launched in Japan

Berry MATCH is a new product in the MATCH line of carbonated vitamin drinks. It is a mix of strawberry, raspberry, blueberry, cranberry and black currant.

My Size Iine Plus" Line with "Chuka-Don for People Concerned about Salt," "Minced Chicken and Egg Rice Bowl for People Who Want to Get Protein," and "European Style Curry for People Concerned about Blood Sugar Level" launched

Otsuka Foods India Private Limited established

Zero Meat, soy protein hamburger launched in Japan

50th Anniversary of Launch of Bon Curry

Shanghai Aozikai Testing Technology Co.,Ltd. Established

”Original Bon Curry" with nostalgic flavor and more vegetables and meat launched

Otsuka Medical Devices Co., Ltd. Established

Otsuka Medical Devices Co., Ltd. furthers the Otsuka group’s medical device business.
Photograph: A stent from MicroPort Scientific Corporation, China

Otsuka Medical Devices Co., Ltd. acquires JIMRO Co., Ltd.

At the time of the formation of Otsuka Medical Devices, JIMRO became a subsidiary

Otsuka Medical Devices Co., Ltd. acquires capital in KiSCO Ltd.

Medical equipment company focused on implant materials

Otsuka Medical Devices Co., Ltd. provides loan to MicroPort Scientific Corporation (MPS) to fund MPS’s acquisition of the hip and knee artificial joint businesses of Wright Medical Group Inc.

Otsuka Medical Devices provides loan to its subsidiary, MicroPort Scientific Corporation (MPS) to fund MPS’s acquisition of the hip and knee artificial joint businesses of Wright Medical Group Inc.

Lilium Otsuka Co., Ltd. Established

Lilium Otsuka Co., Ltd. was established with the aim of developing revolutionary devices in the urology field.

KiSCO Ltd. signs an agreement with Orthorebirth Co., Ltd. for the exclusive sales rights in Japan for ReBOSSIS, a cotton-type synthetic bone-void-filling material

KiSCO Ltd. signed an agreement with Orthorebirth Co,. Ltd. for the exclusive sales rights in Japan for ReBOSSIS, the world’s first cotton-type synthetic bone-void-filling material.

JIMRO Co., Ltd. invested in Biomedical Solutions Inc.

ReCor Medical Inc. became a fully-owned subsidiary of Otsuka Medical Devices

JIMRO received approval for production and sale of Tron FX Thrombectomy Device of Biomedical Solutions Inc.

Otsuka Medical Devices acquired Veryan Medical Ltd. through its UK subsidiary Otsuka Medical Devices UK Ltd.

Otsuka Museum of Art established

The world’s only ceramic board art museum reproducing masterpieces was opened to mark the 75th anniversary of the founding of the Otsuka group. More than 1000 masterpieces of Western art are reproduced in full size replicas in the building, where the display stretches for four kilometers. The museum is also active as a center for all kinds of social and cultural programs, including music recitals, academic conferences, art education and public performances of kabuki.

Clinic for Afghan refugees established in Peshawar, Pakistan

Otsuka group companies in Asia and the Middle East opened and still operate a free clinic for Afghan refugees in Peshawar, Pakistan.

Earth Chemical Co., Ltd. listed on the second section of Tokyo Stock Exchange

Moved to the first section of Tokyo Stock Exchange in 2006.

Tokushima Vortis soccer team promoted to J. League Division 1

Tokushima Vortis, which the Otsuka group supports, was founded in 2004. The team’s long-awaited promotion to J. League Division 1 was finally realized starting with the 2014 season, ten years since the team joined J. League Division 2.

Tokushima Vortis soccer team promoted to J1 Division of Japan Professional Football League (2nd J1 promotion after a hiatus of 7 years)